News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Swine Flu Variation Emerges With Power to Resist Drugs from Roche Holding AG (RHHBF.PK) and GlaxoSmithKline (GSK)



6/10/2011 8:19:20 AM

A novel form of the swine flu virus that swept the globe in 2009 has emerged in Australia and Singapore, carrying a genetic twist that helps it resist Roche Holding AG (ROG)’s Tamiflu and GlaxoSmithKline Plc (GSK)’s Relenza, researchers said. More than 10 percent of the infections in Singapore and 30 percent of those in northern Australia tested in early 2011 had mildly reduced sensitivity to the two drugs that are the mainstay of influenza treatment, according to a report today from the World Health Organization’s influenza research group in North Melbourne, Australia. BioCryst Pharmaceuticals Inc. (BCRX)’s experimental flu drug peramivir remained an effective treatment against the virus in laboratory tests, the researchers said.

Read at Bloomberg
Read at SF Gate
Read at Reuters
Read at Canadian Press


comments powered by Disqus
   
Swine Flu

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES